ARWR · Arrowhead Pharmaceuticals
AI read · Neutral
The AI's read
The rating supports confidence in Arrowhead, but the lower target points to a less favorable view of its shares. The story gives no new company results to settle the disagreement.
Morgan Stanley still thinks Arrowhead Pharmaceuticals is a good buy but has lowered its price target to $106.
Neutral
Morgan Stanley kept its Buy rating but lowered its price target. The two views point in different directions, and the story reports no new company results to resolve them.
Get alerts for ARWR
Follow Arrowhead Pharmaceuticals (ARWR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ARWRFree on the App Store and Google Play, or on the web.